UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of a controlled human infection model to study respiratory syncytial virus infection in older adults

The Lancet. Healthy longevity, 2022-06, Vol.3 (6), p.e370-e371

Sande, Charles J

2022

Volltextzugriff (PDF)

Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya

PloS one, 2017-05, Vol.12 (5), p.e0177803-e0177803

2017

Volltextzugriff (PDF)

Respiratory syncytial virus: diagnosis, prevention and management

Therapeutic Advances in Infectious Disease, 2019, Vol.6

2019

Volltextzugriff (PDF)

The long-term efficacy of a respiratory syncytial virus vaccine for older adults

The Lancet infectious diseases, 2024-09, Vol.24 (9), p.941-942

Sande, Charles J

2024

Volltextzugriff (PDF)

Airway response to respiratory syncytial virus has incidental antibacterial effects

Nature communications, 2019-05, Vol.10 (1), p.2218-2218, Article 2218

2019

Volltextzugriff (PDF)

Implementation strategies for passive respiratory syncytial virus immunisation

The Lancet infectious diseases, 2021-09, Vol.21 (9), p.1200-1201

Sande, Charles J

2021

Volltextzugriff (PDF)

Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects

Nature communications, 2019-07, Vol.10 (1), p.3291-1, Article 3291

2019

Volltextzugriff (PDF)

Priorities for developing respiratory syncytial virus vaccines in different target populations

Science translational medicine, 2020-03, Vol.12 (535)

2020

Volltextzugriff (PDF)

Development of respiratory syncytial virus (RSV) vaccines for infants

The Journal of infection, 2017-06, Vol.74 (Suppl 1), p.S143-S146

2017

Volltextzugriff (PDF)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

Science translational medicine, 2015-08, Vol.7 (300), p.300ra126

2015

Volltextzugriff (PDF)

Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya

Wellcome open research, 2019, Vol.4, p.33-33

2019

Volltextzugriff (PDF)

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

The Journal of infection, 2019-05, Vol.78 (5), p.382-392

2019

Volltextzugriff (PDF)

Vaccination against Respiratory Syncytial Virus

Interdisciplinary topics in gerontology and geriatrics, 2020, Vol.43, p.182-192

2020

Volltextzugriff (PDF)

Untargeted analysis of the airway proteomes of children with respiratory infections using mass spectrometry based proteomics

Scientific reports, 2018-09, Vol.8 (1), p.13814-9, Article 13814

2018

Volltextzugriff (PDF)

Genetic Relatedness of Infecting and Reinfecting Respiratory Syncytial Virus Strains Identified in a Birth Cohort From Rural Kenya

The Journal of infectious diseases, 2012-11, Vol.206 (10), p.1532-1541

2012

Volltextzugriff (PDF)

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants

Vaccine, 2014-08, Vol.32 (37), p.4726-4729

2014

Volltextzugriff (PDF)

Best practice in the prevention and management of paediatric respiratory syncytial virus infection

Therapeutic Advances in Infectious Disease, 2016-04, Vol.3 (2), p.63-71

2016

Volltextzugriff (PDF)

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection

Vaccine, 2018-11, Vol.36 (46), p.6988-6994

2018

Volltextzugriff (PDF)

RSV vaccine use - the missing data

Expert review of vaccines, 2016-02, Vol.15 (2), p.149-152

2016

Volltextzugriff (PDF)

Group- and Genotype-Specific Neutralizing Antibody Responses Against Respiratory Syncytial Virus in Infants and Young Children With Severe Pneumonia

The Journal of infectious diseases, 2013-02, Vol.207 (3), p.489-492

2013

Volltextzugriff (PDF)

Defining the vaccination window for respiratory syncytial virus

PloS one, 2017-05, Vol.12 (5), p.e0177803

2017

Volltextzugriff (PDF)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

Cancer, 2021-03, Vol.127 (6), p.884-893

2021

Volltextzugriff (PDF)

New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March–May 2023

Emerging infectious diseases, 2023-11, Vol.29 (11), p.2376-2379

2023

Volltextzugriff (PDF)

Prospective Observational Study of Incidence and Preventable Burden of Childhood Tuberculosis, Kenya

Emerging infectious diseases, 2018-03, Vol.24 (3), p.514-523

2018

Volltextzugriff (PDF)

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

The Lancet infectious diseases, 2023-01, Vol.23 (1), p.e2-e21

2023

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Humans
(53)
Life Sciences & Biomedicine
(53)
Female
(29)
Male
(26)
Respiratory Syncytial Virus
(20)
Middle Aged
(17)
Biological And Medical Sciences
(16)
Aged
(15)
Infant
(15)
Urology & Nephrology
(15)
Immunology
(14)
Medical Sciences
(14)
Infections
(13)
Infectious Diseases
(13)
Adult
(12)
Child, Preschool
(12)
Vaccines
(12)
Infants
(11)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Development of a controlled human infection model to study respiratory syncytial virus infection in older adults

Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya

Respiratory syncytial virus: diagnosis, prevention and management

The long-term efficacy of a respiratory syncytial virus vaccine for older adults

Airway response to respiratory syncytial virus has incidental antibacterial effects

Implementation strategies for passive respiratory syncytial virus immunisation

Author Correction: Airway response to respiratory syncytial virus has incidental antibacterial effects

Priorities for developing respiratory syncytial virus vaccines in different target populations

Development of respiratory syncytial virus (RSV) vaccines for infants

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

Agreement between ELISA and plaque reduction neutralisation assay in Detection of respiratory syncytial virus specific antibodies in a birth Cohort from Kilifi, coastal Kenya

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults

Vaccination against Respiratory Syncytial Virus

Untargeted analysis of the airway proteomes of children with respiratory infections using mass spectrometry based proteomics

Genetic Relatedness of Infecting and Reinfecting Respiratory Syncytial Virus Strains Identified in a Birth Cohort From Rural Kenya

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants

Best practice in the prevention and management of paediatric respiratory syncytial virus infection

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection

RSV vaccine use - the missing data

Group- and Genotype-Specific Neutralizing Antibody Responses Against Respiratory Syncytial Virus in Infants and Young Children With Severe Pneumonia

Defining the vaccination window for respiratory syncytial virus

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March–May 2023

Prospective Observational Study of Incidence and Preventable Burden of Childhood Tuberculosis, Kenya

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Suchergebnisse filtern